Segment Information - Additional Information (Details) $ in Thousands |
6 Months Ended | |
|---|---|---|
|
Jun. 30, 2025
USD ($)
Segment
|
Jun. 30, 2024
USD ($)
|
|
| Segment Reporting Information [Line Items] | ||
| Number of operating segments | Segment | 1 | |
| Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] | srt:ChiefExecutiveOfficerMember | |
| Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description | The CODM assesses performance for the novel oncology therapeutics segment and decides how to allocate resources based on net loss that also is reported on the income statement as consolidated net loss. The measure of segment assets is reported on the balance sheet as cash and cash equivalents.The Company has not generated any product revenue in the current period and expects to continue to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through all stages of development and clinical trials. As such, the CODM uses cash forecast models in deciding how to invest into the novel oncology therapeutics segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results, net cash used in operating activities for the period and cash on hand are used in assessing performance of the segment. | |
| Net cash used in operating activities | $ | $ 13,668 | $ 12,804 |